source
- Revolution Medicines' pancreatic cancer therapy Rasonque moves closer to European approval after FDA clearanceRevolution Medicines' experimental drug Rasonque, aimed at treating pancreatic cancer, has received a recommendation for approval from European regulators. The recommendation follows an earlier po…
- Nouscom secures €120M to advance off-the-shelf cancer vaccine for Lynch syndromeSwiss biotech Nouscom announced a €120 million (about $135 million) Series D financing round. The capital will fund a registration-enabling pivotal trial of its cancer-preventing vaccine candidate.…